WebNov 14, 2024 · EQS-News: Biotest AG / Key word(s): Regulatory Approval Biotest AG: Biotest receives approval for new intravenous immunoglobulin Yimmugo® (IgG Next Generation) 14.11.2024 / 09:30 CET/CEST The issuer is solely responsible for the content of this announcement. WebDas Bundeskartellamt hat die Übernahme desPlasmaherstellers Biotest durch den spanischen Konzern Grifolserlaubt – und dabei lobende Worte gefunden: Denn durch denAusstieg des chinesischen Eigentümers …
Grifols completes the acquisition of Biotest: a strategic …
WebNov 14, 2024 · As of the publication date, 8 November 2024, Biotest AG opened seven new plasma collection centres to improve the supply of our sustainable raw material plasma. Biotest will publish the complete figures for the first nine months of the 2024 financial year on 14 November 2024. WebNov 20, 2024 · "Biotest is expanding its immunoglobulin product portfolio with an innovative new product. Yimmug offers patients and physicians another important treatment option whose safety, efficacy and tolerability have been proven in the approval studies," emphasises Dr Jörg Schüttrumpf, Chief Scientific Officer of Biotest AG. how to stop facebook tracking my web browsing
Biotest AG at a glance
WebMay 27, 2008 · The Managing Board of Biotest AG raised the company's forecast for turnover and profit in the current year. The Management now expects sales of EUR 420 million in 2008, following EUR 326.4 million ... WebDie Biotest Aktiengesellschaft mit Sitz in Dreieich ist ein börsennotierter Anbieter von Arzneimitteln, ... das bis heute vermarktet wird. 1986 kam es zur Umwandlung der … WebMar 30, 2024 · Biotest AG today announced that the last planned interim analysis in its phase III trial AdFIrst (Adjusted Fibrinogen Replacement Strategy) has been successfully completed. The AdFIrst trial is a prospective, randomised, active-controlled, multicentre phase III trial investigating the efficacy and safety of Biotest’s human fibrinogen ... reactive pvd